NCT04618913 2026-03-12
VICTORIE
Pfizer
Active not recruiting
Clinical Trials
20 trialsNCT07270263 2025-12-26
HEM-DOAC
Medical University of Gdansk
Phase NA Recruiting
NCT06220123 2025-07-22
A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
Beijing Suncadia Pharmaceuticals Co., Ltd
Phase 2 Completed
NCT06580223 2025-07-18
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3 Not yet recruiting
NCT05920343 2025-07-10
PREVENT-GU
Ottawa Hospital Research Institute
Phase 2/3 Recruiting
NCT05029063 2025-07-09
TRIM-Line
Ottawa Hospital Research Institute
Phase 3 Recruiting
NCT04979780 2024-10-31
OSCAR-US
Bayer
Completed
NCT06314763 2024-04-30
ROSIE
Radboud University Medical Center
Phase 4 Completed
NCT06196918 2024-01-09
Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients
Nanfang Hospital, Southern Medical University
Phase NA Unknown
NCT05150938 2023-12-18
A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)
Bayer
Completed
NCT02744092 2023-10-03
CANVAS
Alliance Foundation Trials, LLC.
Phase NA Completed
NCT05112666 2023-04-03
A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)
Bayer
Completed
NCT05461807 2022-10-26
H2H-OSCAR-US
Bayer
Completed
NCT03055026 2022-03-11
PRO-LAPSII
Fadoi Foundation, Italy
Phase 3 Completed
NCT03965741 2021-11-30
PRACTISE
Bayer
Completed
NCT04999176 2021-08-10
VALERIA
Science Valley Research Institute
Phase 3 Unknown
NCT02583191 2021-05-03
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
AIO-Studien-gGmbH
Phase 3 Terminated
NCT02555878 2019-09-12
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
Janssen Research & Development, LLC
Phase 3 Completed
NCT03214172 2018-09-06
Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban
Bayer
Completed
NCT02746185 2018-08-13
CASTA-DIVA
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed